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Abstract: Breast cancer is one of the most common causes of mortality in women. Flavonoids, among other compounds, are bioactive constituents of propolis. 
In this comparative study, we investigated the effects of flavonoids apigenin (API), genistein (GEN), hesperidin (HES), naringin (NAR) and quercetin (QUE) on 
the proliferation, apoptosis, and cell cycle of two different human cancer cells - MDA-MB-231, estrogen-negative, and MCF-7, estrogen-positive receptor breast 
carcinoma cells. Many cytotoxic reports of flavonoids were performed by MTT assay. However, it’s reported that MTT is reduced in metabolically active cells and 
yields an insoluble purple formazan, which indicates that obtained cytotoxic results of flavonoids could be inconsistent. Cell viability was measured by NR, neutral 
red assay, while the percentage of apoptotic cells and cell cycle arrest were determined by flow cytometry and Muse cell cycle assay, respectively. The results 
showed a high dose-dependent effect in cell viability tests. IC50 values were as follows (MCF-7/MDA-MB-231, for 48 h, in µM): 9.39/50.83 for HES, 25.19/88.17 
for API, 40.26/333.51 for NAR, 49.49/47.50 for GEN and 95.12/130.10 for QUE. Flavonoid-induced apoptosis was dose- and time-dependent, for both cancer cell 
lines, though flavonoids were more active on MCF-7 cells. The flavonoids also induced cell cycle arrest in cancer cells.
Key words: Flavonoids; Propolis; Breast cancer.
Introduction
Breast cancer is one of the most common causes of 
mortality among women. Worldwide, this malignancy 
ranks as the fifth leading cause of cancer related deaths. 
Among inhabitants of less developed countries it is the 
leading cause of death (324,000 deaths, 14.3% of can-
cer mortality). In more developed regions of the world 
breast cancer ranks second just after lung cancer as to 
cancer related deaths (198,000 deaths, 15.4% of cancer 
related mortality). In the next 10 years, the number of 
breast cancer patients are expected to exceed an addi-
tional 20,000 per year (1).
Breast cancer is a heterogeneous group of tumors. 
Recently, numerous personalized therapies against 
breast cancer have been implemented which have 
proven effective (2). Among the molecular subtypes of 
breast cancer, recently much attention has been placed 
on triple-negative breast cancer (TNBC), derived from 
cells characterized by lack of expression of both steroid 
receptors (estrogen receptors - ER, and progesterone 
receptors-PR), as well as the human epidermal growth 
factor-2 (HER-2) receptor (3-6). TNBC totals approxi-
mately 9% of total breast cancers treated surgically (7). 
Many patients with this type of cancer have an extreme-
ly poor prognosis due to low remission during adjuvant 
therapy and in cases of metastases, a short survival time 
and high resistance to chemotherapy (8-13). Hormonal 
and targeted therapy against TNBC is highly problem-
atic, depending on the specific cell signaling pathways 
(14-19).
Recently, an increased interest in natural chemopre-
ventive agents has been observed (20). Natural prod-
ucts, rich in bioactive compounds are now being used 
for both cancer chemoprevention and chemotherapy. 
Presently, over 70% of anticancer drugs used are de-
rived from natural compounds. The progress of nano-
targeted therapy also increases the efficacy of natural 
products by a combination of monoclonal antibodies or 
polymeric carriers (21).
Propolis, a naturally occurring antibiotic is processed 
by bees. Its composition and properties are variable and 
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depend on the geographical origin of the substance 
(22-24). Research has shown that propolis possesses 
antimicrobial, anti-inflammatory, immune-stimulatory, 
antiviral and hepatoprotective activities. These proper-
ties have been mostly ascribed to flavonoids, a group of 
natural compounds contained in propolis (25-32). It is 
noteworthy that both in vitro and in vivo studies have 
recently documented the anticancer activity of propo-
lis, as well as its mechanism of action in relation to the 
phytochemical composition (33-36). These studies have 
demonstrated both the anticarcinogenic properties of 
propolis and its biologically active compounds (includ-
ing flavonoids) against different cancer cell lines (37, 
38).
Flavonoids are polyphenols which contain fifteen 
carbon atoms. Their carbon skeleton consists of two 
benzene (A and B) rings connected by a short three 
carbon chain (C6-C3-C6). One of the carbons in this 
chain is connected to a carbon atom in one of the ben-
zene rings, either through an oxygen bridge or directly, 
which produces a third heterocyclic middle (C) ring. 
The main classes of flavonoids (flavanones, flavones, 
flavonols, flavanols, isoflavonoids and anthocyanidins) 
differ in their level of oxidation and saturation of the C 
ring, while individual compounds within this class vary 
in their substitution pattern of the A and B rings. Fla-
vonoids are powerful antioxidants, with the ability to 
scavenge free radicals, chelate transition metal ions and 
inhibit the enzymes responsible for this chain reaction 
initiation (39-43). Both preclinical and clinical studies 
have reported antimicrobial, antioxidant, anti-inflam-
matory, anticancer, antiatherosclerotic, antiallergic, an-
ti-platelet and anti-hypertensive activities of flavonoids 
(44-47). Aside from this antioxidant ability, the antican-
cer potential of flavonoids also depends on their abil-
ity to interact with Phase I and II enzymes involved in 
procarcinogen biotransformation, as well as their abil-
ity to inhibit the enzymes involved in DNA replication. 
Additionally, flavonoids modulate cyclin activity, thus 
arresting cell cycle (phases G1/S or G2/M), inhibiting 
cancer cell proliferation and inducing apoptosis (48).
Our research has compared the cellular response 
of human breast adenocarcinoma MDA-MB-231 and 
MCF-7 cells to five flavonoids, which normally occur 
in propolis: apigenin (API), genistein (GEN), hesperi-
din (HES), naringin (NAR) and quercetin (QUE), all of 
which are representatives of different subclasses (Table 
1). The chemical structures of the flavonoids tested are 
shown in Figure 1.
To the best of our knowledge, this is the first time 
such comparative research has been performed. In this 
study, we investigated cytotoxic and proapoptotic acti-
vities of selected flavonoids, representative of different 
subclasses, as well as the induction of cell cycle arrest. 
Flavonoids, which occur in propolis and other honey 
bee products is the subject of our specific research in-
terest. In earlier studies, we compared two other com-
ponents of propolis: caffeic acid (CA) and caffeic acid 
phenethyl ester (CAPE), which inhibited migration rate, 
induced apoptosis and cell cycle arrest in the breast can-
cer MDA-MB-231 cells; in particular, CAPE exhibited 
better activity against TNBC (38, 71).
Materials and Methods
Cell lines and reagents
Breast cancer cell cultures
Two breast adenocarcinoma cell lines, from Cauca-
sian females were used: MCF-7 and MDA-MB-231, 
the latter being a model of human triple-negative breast 
cancer (TNBC). MCF-7 cells (human breast adenocar-
cinoma, no. 86012803 SIGMA from Sigma-Aldrich, 
Poznań, Poland) were cultured on Dulbecco’s modi-
fied Eagle’s medium, with 10% inactivated fetal bo-
vine serum (Sigma-Aldrich, Poznań, Poland) and 0.01 
mg·mL−1 bovine insulin (Sigma-Aldrich, Poznań, 
Poland). Cells were incubated at 37 °C in 5% CO2 at-
mosphere. MDA-MB-231 cells (human breast adeno-
carcinoma, TNBC, no. 92020424 SIGMA from Sigma-
Aldrich, Poznań, Poland) were cultured on Leibovitz’s 
L-15 medium with 10% inactivated fetal bovine serum 
(Sigma-Aldrich, Poznań, Poland), at 37 °C without 
CO2. Both cell lines were supplemented with antibiot-
ics: 100 U·mL−1 penicillin, 100 μg·mL−1 confluence of 
80%–90%. All manufacturer’s recommendations for 
preparation were carefully followed.
Flavonoids
Apigenin (No. 01760595 SIGMA), quercetin (No. 
1592409 SIGMA), naringin (No. Y0001378 SIGMA), 
hesperidin (No. Y0001203 SIGMA), genistein (No. 
05360590 SIGMA) were purchased from Sigma-Al-
Flavonoid Flavonoid class Activities References
Apigenin Flavones
antiallergic
anticancer
anti-inflammatory
proapoptotic
(49)
(50, 51)
(52)
(53)
Quercetin Flavonols
proapoptotic
anticancer
anti-inflammatory
antioxidant
(54, 55)
(55, 56)
(56, 57)
(57)
Naringin
Hesperidin
Flavanones
proapoptotic
anticancer
antioxidant
anti-inflammatory
chemopreventive
(58)
(59)
(59, 60)
(60)
(61, 62)
Genistein Isoflavones
anticancer
proapoptotic
(63-65)
Table 1. Flavonoids existing in propolis, and their activities.
Figure 1. Chemical structures of flavonoids (66-70).
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less than 0.05 were considered statistically significant.
Results
Cytotoxic effects of selected flavonoids on MDA-
MB-231 and MCF-7 cells
Cytotoxicity of the tested flavonoids was measured 
by NR (Neutral Red) assay. The results are presented in 
Figure 2. A strong dose-dependent trend is clearly indi-
cated. 
For the MDA-MB-231 cells, only mild cytotoxic ac-
tivity was observed for 24 h (Figure 2a). Using a dose 
of 5 µM, only HES exposed significant activity on the 
MDA-MB-231 cells, reaching a viability of 88.4%. In-
creasing doses of all flavonoids resulted in viability in-
hibition of MDA-MB-231 cells, though QUE, even at a 
dose of 10 µM, showed no significant cytotoxic activity 
against MDA-MB-231 cells after 24 h. No flavonoids 
were below the 65% line (HES reached a minimum 
value of 68.2%). 
Increasing incubation time to 48 h resulted in an 
evident viability decline from the lowest doses for 
MDA-MB-231 samples (Figure 2b). The values of cell 
viability decreased proportionally as the doses were in-
creased. With a dose of 100 µM the following values, 
ordered from lowest to highest, were: HES – 39.5%, 
GEN – 42.2%, and API – 48.4%, QUE - 48.7% and 
NAR: 60.5%
Against the MCF-7 cell line, almost all flavonoids 
exhibited higher cytotoxicity than on MDA-MB-231 
cells after 24 h (Figure 2c). The viability of the MCF-7 
cells decreased in a dose-dependent manner. All doses, 
of all tested flavonoids, resulted in a significant viability 
inhibition. QUE exhibited slightly higher cytotoxic ac-
tivity against MCF-7 than MDA-MB-231 cells, reach-
ing its minimum of 62.3% at a dose 100 µM, compared 
to 71.1% against MDA-MB-231 cells, after 24 h with 
the same dosage. The highest cytotoxic activity was 
seen with HES, at 19.4% with a 100 µM dose after 24 h. 
The viability values of MCF-7 cells were the lowest 
at 48 h (Figure 2d). HES showed strong activity even 
with a 5 µM dose, with a value of 62.9%. The dose-
dependent trend remained. With the highest 100 µM 
dosage, the flavonoids reached the following viability 
drich, Poznań, Poland, and they were all stored, col-
lected, and used strictly according to the manufacturer’s 
instruction.
Cytotoxicity by lyzosomal activity, NR test assay
NR is a weak cationic dye that, relatively easily, pen-
etrates the cell membrane and accumulates intracellu-
larly in lysosomes (lysosomal pH < cytoplasmic pH), 
where it binds to the lysosomal matrix anionic sites. 
Therefore, this assay can be used to measure cell vi-
ability.
The sensitivity of the lysosome and other effects 
that gradually become irreversible are due to cell sur-
face changes and lysosomal membrane sensitivity. Such 
changes caused by xenobiotics result in a reduction in 
NR uptake binding. Therefore, using this method can 
distinguish viable, damaged or dead cells (72). The 
NR test was obtained from Xenometrix AG, Allschwil, 
Switzerland. We used flavonoids at concentrations of 50 
µM and 100 µM, with 24 h and 48 h of incubation. The 
quantity of dye incorporated into cells was measured by 
spectrometry at 540 nm, and is directly proportional to 
the quantity of cells of an intact membrane. Procedure 
of the test was performed exactly in accordance to the 
manufacturer‘s instruction and protocol. 
Apoptosis detection: Muse® annexin V and dead cell 
assay
Briefly, both cell lines were seeded in 6 well plates, 
with an amount of 5 × 105 cells/well, grown for 72 h to 
obtain logarithmic growth. The cells were incubated in 
a complete culture medium containing flavonoids (50 
and 100 µM) for 24 h and 48 h. Then, 1 × 106 cells in 
suspension were transferred to a new tube and incubated 
with 100 µL of Annexin V & Dead Cell Reagent (Merck 
Millipore, Warsaw, Poland) for 20 min. at room tem-
perature. Pure medium was used as a control. Apoptosis 
was determined by Muse® Cell Analyzer, Millipore, 
Billerica, MA, USA (emission max: yellow-red 576 and 
680 nm; excitation max: 532 nm).
Muse® cell cycle assay
This assay was performed according to the manufac-
turer's instructions. Briefly, cells were plated at 1 x 104 
cells/well and incubated in a medium containing 10% 
FBS (fetal bovine serum) at 37°C. Then, the cells were 
incubated in a medium containing flavonoids, at mea-
sures of 50 and 100 µM, for 24 h and 48 h. Finally, the 
cells were washed with PBS (phosphate-buffered saline) 
and centrifuged, then cold, freshly prepared 70%-etha-
nol was poured and samples were maintained at 20°C 
until analysis. Afterwards, cells were washed with PBS 
and further processed for cell cycle analysis in accor-
dance with the manufacturer's instructions.
Statistical analysis
All results were expressed as means ± SD obtained 
from three separate experiments and performed in qua-
druplicates (n=12). The results were performed with in-
dependent sample t-tests. The experimental means were 
compared to the means of untreated cells harvested in 
a parallel manner. Differences between control and 24 
or 48 h incubated samples, were tested for significance 
using the one-way Friedman ANOVA test. A p-value 
Figure 2. The cytotoxic activity of apigenin, genistein, hesperidin, 
naringin and quercetin were tested using concentrations from 5 to 
100 µM with 24 (a, c) and 48 (b, d) h incubation times, on the 
breast cancer cell lines, MDA-MB-231 (a, b) and MCF-7 (c, d). 
Cell viability was analyzed by NR assay. The results were pres-
ented as mean and standard deviation of three independent expe-
riments, with 12 wells each (* p <0.05; Friedman ANOVA test).
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values: API: 18.43%, GEN: 40.8%, HES: 8.4%, NAR: 
30.2% and QUE: 48.2%.
For all flavonoids, IC50 was calculated on both breast 
cancer cell lines. The 50%-mortality results are shown 
in Table 2.
It can be clearly observed that the tested flavonoids 
showed higher cytotoxic activity against MCF-7 cells 
and displayed a dose- and time dependent trend. 
For the MDA-MB-231 line, the flavonoids ordered 
according to their decreasing cytotoxic activity are as 
follow: GEN > HES > API > QUE > NAR. For the 
MCF-7 line, the cytotoxic activity of the tested flavo-
noids decreased as follow: HES > API > NAR > GEN 
> QUE.
Apoptotic effects of selected flavonoids on MDA-
MB-231 and MCF-7 Cells
For subsequent experiments, only flavonoids with 
the highest concentrations, i.e. 50 and 100 µM, were 
used.
For the MDA-MB-231 cells, all tested flavonoids 
significantly decreased the percentage of live cancer 
cells and an apoptotic effect was recorded after 24 h of 
incubation (Figure 3a). All flavonoids induced apopto-
sis in a dose-dependent manner, except HES, although 
its increased dosage resulted in an increased amount 
of dead cells. For doses of 50 µM, the percentage of 
MDA-MB-231 apoptotic cells were: API - 9.52%, QUE 
- 12.29%, NAR - 12.64%, GEN - 14.46%, with the high-
est value displayed by HES - 22.89%. In the same cells, 
after 24 h, 100 µM flavonoids induced apoptosis as fol-
lows: API - 15.40%, NAR - 16.78%, GEN - 16.89%, 
QUE - 21.62% and HES - 21.99%. 
During the 48-h experiment (Figure 3b), the per-
centage of MDA-MB-231 cells with live phenotype de-
creased significantly and all flavonoids induced apop-
tosis. Apart from HES and GEN, other flavonoids trig-
gered apoptosis with a dose-dependent trend. Indeed, 
HES and GEN were more active at 50 than 100 µM, 
though, again, the number of dead cells significantly 
increased at the highest concentration. Therefore, after 
48 h of incubation, the percentages of MDA-MB-231 
apoptotic cells were: NAR - 18.37%, GEN - 18.46%, 
QUE - 20.47%, API - 25.70% and HES - 38.37% for 
doses of 50 µM. In the same cells, for the dose of 100 
µM, the values were: GEN - 6.55%, NAR - 22.23%, 
API - 28.82%, HES - 32.90% and QUE - 36.29%.
All results of apoptosis in the MDA-MB-231 cells 
are shown in Figure 3.
All tested flavonoids showed an apoptotic effect 
against MCF-7 cells, both at 24 h and 48 h of incubation 
(Figure 4). In particular, after 24 h treatment, all flavo-
noids decreased the percentage of live cancer cells and 
significantly induced dose-dependent apoptosis, except 
for HES, which again resulted in an increased amount of 
dead cells with increased dosage (Figure 4a). For doses 
of 50 µM, the percentages of MCF-7 apoptotic cells 
were as follow: QUE - 12.26%, GEN - 26.36%, NAR 
- 35.86%, API - 36.15% and HES - 57.10%. Apoptosis 
Flavonoids MDA-MB-231 cell line
Time of incubation
24 h 48 h
Apigenin >1000 88.17
Genistein 802.64 47.50
Hesperidin >1000 50.83
Naringin 913.99 333.51
Quercetin >1000 130.10
Flavonoids MCF-7 cell line
24 h 48 h
Apigenin 38.84 25.19
Genistein 139.43 49.49
Hesperidin 22.14 9.39
Naringin 82.54 40.26
Quercetin 661.07 95.12
Table 2. IC50 (µM) values of flavonoids on MDA-MB-231 and 
MCF-7 breast cancer cell lines.
Figure 3. Apoptotic effect of flavonoids on MDA-MB-231 at 50 
µM and 100 µM, after 24 h (a) and 48 h (b) of incubation. Apop-
tosis was measured by Muse® Annexin V and Dead Cell Assay. 
All values are presented as means, and vertical bars represent the 
standard deviation of means (SD) (n = 3 experiments); *p < 0.05.
Figure 4. Apoptotic effect of flavonoids on MCF-7 cells at 50 µM 
and 100 µM, after 24 h (a) and 48 h (b) of incubation. Apopto-
sis was measured by Muse® Annexin V and Dead Cell Assay. All 
values are presented as means, and vertical bars represent the stan-
dard deviation of means (SD) (n = 3 experiments); *p < 0.05.
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was also induced in the same cells treated with flavo-
noids at 100 µM, after 24 h incubation: QUE - 19.79%, 
GEN - 28.64%, NAR - 39.95%, API - 41,71% and HES 
- 51.48%.
During the 48-h experiment (Figure 4b), the percen-
tage of MCF-7 cells with live phenotype decreased and 
apoptosis was significantly induced by all flavonoids. 
At these conditions, only QUE and, above all, HES 
dose-dependently activated apoptosis. All other flavo-
noids exhibited apoptosis induction with a slight dose-
dependent trend. Percentages of apoptotic MCF-7 cells 
were: QUE - 33.39%, GEN - 40.11%, HES - 52.15%, 
API - 57.45% and NAR - 58.39% for doses of 50 µM. 
In the same cells, 24 h after incubation with the highest 
flavonoid concentration, percentages of apoptotic cells 
were: GEN - 21.30%, QUE - 35.66%, NAR - 49.28%, 
API - 50,01% and HES - 70.47%.
Effects of selected flavonoids on cell cycle in MDA-
MB-231 and MCF-7 Cells
In MDA-MB-231 cells, after 24 h of incubation 
(Figure 5a), 50 µM API induced cell cycle arrest in the 
G2/M phase in a dose-dependent manner, reaching val-
ues of 28.00% for S-phase and 14.57% for G2/M. At 100 
µM of API, the value of S-phase declined to 17.30%, 
while G2/M increased to 22.50%. The values of the G0/
G1 phase showed slight change. 50 µM QUE decreased 
the number of cells in the S-phase to 24.17%, while the 
G2/M-phase increased to 17.43%. 100 µM QUE only 
slightly affected cell cycle: 27.90% and 19.40% cells 
were in S-phase and G2/M, respectively. Only 100 µM 
HES significantly changed cell cycle progression: the 
percentage of cells in G0/G1 phase declined to 34.40%, 
while increasing to 39.67% and 25.77% in S-phase and 
G2/M, respectively. 50 µM NAR and 50 µM GEN re-
sulted in only slight changes of the cell cycle: NAR 
showed 44.20% for the S-phase and 11.97% for the 
G2/M, while GEN showed 26.73% for the S-phase and 
20.03% for the G2/M. At 100 µM, no significant chang-
es were recorded: NAR was 45.03% for the S-phase 
and 9.90% for G2/M, while GEN was 26.87% for the 
S-phase and 16.10% for the G2/M phase. However, 100 
µM GEN arrested cell cycle at the G0/G1 checkpoint 
(56.90%).
In MDA-MB-231 cells, after 48 h of incubation 
(Figure 5b), 50 µM API exhibited slight effects on cell 
cycle progression, with 53.73%, 31.53% and 14.63% 
of cells in the G0/G1 phase, S-phase and G2/M. QUE 
induced a weak decrease of the number of cells in the 
G0/G1 phase (54.83% at 50 µM, and 53.40% at 100 
µM) and cell cycle arrest in the S-phase (36.63% at 50 
µM, and 34.97% at 100 µM). The cells in G2/M phase 
increased from 8.47% for 50 µM QUE to 11.53% for 
100 µM QUE. For HES, the number of cells in the S-
phase declined from 46.67% (50 µM) to 39.57% (100 
µM). Cells in G2/M phase were 11.07% after incubation 
with 50 µM HES, whereas the highest concentration of 
this flavonoid significantly increased the percentage of 
cells in phase G0/G1 (50.77%). Only 100 µM NAR 
significantly affected cell cycle, with 59.17%, 33.67% 
and 6.63% of cells in G0/G1 phase, S-phase and G2/M 
phase, respectively. For GEN as well, the cell cycle was 
arrested at the G0/G1 checkpoint, with the values of 
56.37% for 50 µM and 64.60% for 100 µM.
In MCF-7 cells, after 24 h of incubation (Figure 6a), 
API induced cell cycle arrest in the G0/G1 phase, in a 
dose dependent manner, with 53.47% and 63.90% of 
cells at 50 µM and 100 µM, respectively. A dose-depen-
Figure 5. Effects of flavonoids at 50 µM and 100 µM on MDA-
MB-231 cell cycle arrest after 24 h (a) and 48 h (b) of incubation. 
Cells were stained with Muse® Annexin V and Dead Cell kit and 
analyzed by flow cytometry with 10,000 events collected. The ver-
tical bars represent the standard deviation of means (SD) (n = 3 
experiments); *p < 0.05 value.
Figure 6. Effects of flavonoids at 50 µM and 100 µM on MCF-7 
cell cycle arrest after 24 h (a) and 48 h (b) of incubation. Cells 
were stained with Muse® Annexin V and Dead Cell kit and ana-
lyzed by flow cytometry with 10,000 events collected. The vertical 
bars represent the standard deviation of means (SD) (n = 3 experi-
ments); *p < 0.05 value.
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dent depletion of cells in G2/M was also observed. QUE 
treatment resulted in an increase of percentages of cells 
in the G0/G1 and G2/M phases, in a dose-dependent 
manner. The values were: G0/G1 - 51.00% and 53.17%, 
G2/M - 14.23% and 20.40%, for 50 µM and 100 µM, 
respectively. For HES, with a dose of 50 µM, cells in 
the G0/G1 phase increased to 60.00% with a slight de-
pletion of cells in G2/M to 6.20%. Increasing the dose 
to 100 µM, cells in the S-phase decreased to 30.77% 
and cells in G2/M increased to 9.97%. Treatment with 
NAR decreased the cells in the S-phase, compared with 
control, to 32.03% and 28.23%, for dosages of 50 and 
100 µM, respectively. Cells in the G2/M phase reached 
a value of 15.0% for 50 µM NAR and remained stable 
at 100 µM NAR (15.73%). Once more, GEN resulted in 
cell cycle arrest at the G0/G1 checkpoint, in a dose-de-
pendent manner, with 58.63% and 62.20% of cells at 50 
µM and 100 µM, respectively. The S-phase decreased to 
32.60% and 22.17% for 50 µM GEN and 100 µM GEN 
respectively.
In MCF-7 cells, after 48 h of incubation (Figure 6b), 
API induced a dose-dependent cell cycle arrest in the 
G0/G1 phase, with 65.17% and 65.90% of cells at 50 
µM and 100 µM, respectively. A dose-dependent deple-
tion of cells in S-phase was also observed. QUE treat-
ment dose-dependently increased the number of cells in 
the G2/M phase and S-phase, namely G2/M - 15.13% 
and 25.93%, S - 31.77% and 39.27%, for doses of 50 
and 100 µM, respectively. For HES, with a dose of 50 
µM, the cells in the G0/G1 phase increased to 48.50%. 
Increasing the dose to 100 µM, the cells in the S-phase 
decreased to 36.87%, whereas cells in the G0/G1 in-
creased to 54.80%.
Treatment with 100 µM NAR decreased the cells in 
the S-phase to 27.13%, whereas the cells in the G2/M 
phase dose-dependently increased to 15.73% and 
27.90% at 50 µM and 100 µM, respectively. Finally, 
100 µM GEN resulted in significant cell cycle arrest 
at the G0/G1 checkpoint, with 67.00% of cells. The S-
phase decreased to 28.63% and 20.30%, at 50 µM and 
100 µM, respectively.
Discussion
Constituents of honey bee propolis may vary de-
pending on the region of origin. In this comparative 
study, we investigated flavonoids naturally occur in 
propolis, i.e. API, GEN, HES, NAR and QUE on the 
proliferation, apoptosis as well as cell cycle of MDA-
MB-231 (estrogen receptor negative) and MCF-7 (es-
trogen receptor positive) human breast carcinoma cell 
lines. Recently, we compared other bioactive flavonoid 
agents also found in propolis: caffeic acid (CA) and its 
ester (CAPE) (38). Flavonoids exhibit a broad spectrum 
of biological activity, including multitarget anticancer 
and cancer preventive properties (73). In vitro studies 
on flavonoids have encouraged the research for their use 
in chemoprevention, though their bioavailability needs 
to be further investigated. The cytotoxic activity of di-
etary flavonoids on different human cancer types was 
reviewed by Sak (74). Bai et al. (75) showed API cyto-
toxicity on MCF-7 cells, assessed by MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), 
although using higher API concentrations and incuba-
tion times (up to 72 h). Noteworthy, as MTT is reduced in 
metabolically active cells and yields an insoluble purple 
formazan, the reported cytotoxic effects of flavonoids 
measured by MTT assay could be inconsistent and need 
of further study (76). Uifălean et al. (77) reported the 
cytotoxic activity of GEN on MDA-MB-231 and MCF-
7 cells, after 72 h while we achieved similar effects after 
48 h of GEN treatment. The dose-dependent cytotoxic-
ity of HES was demonstrated by Febriansah et al. (78) 
on MCF-7 cells. Noteworthy, they measured 0 % cell 
viability after treatment with 50 µM of HES, after 24 h, 
while we determined the lowest cell viability with 100 
µM at 48 h. QUE exhibited a dose-dependent growth 
inhibition both on MCF-7 and MDA-MB-231 cells after 
24 and 48 h. Furthermore, according to Ranganathan et 
al. (79), and in line with our results, QUE was less ef-
fective on MDA-MB-231 cells compared with MCF-7 
cells. Finally, NAR was protective for neuronal PC12 
cells against hydrogen peroxide-induced cytotoxicity 
(80) in a dose dependent manner.
Bai et al. (75) showed similar results on MCF-7 
cells, after 24 h of API treatment. Particularly, at 100 
µM, the flavonoid increased late apoptotic cells by 17%, 
less than in our experimental conditions, while the num-
ber of early apoptotic cells was similar to our measure-
ments with 50 µM of API. Tsuboy et al. (81) reported 
that doses of 10 and 25 µM of GEN did not induce 
apoptosis in the MCF-7 cell line which may well be due 
to the lower concentrations of flavonoid they used in 
their experiments.
In experimental colon carcinogenesis, HES induced 
both apoptotic and autophagic cell death (82). This fla-
vonoid also exhibited proapoptotic activity in the human 
hepatocellular carcinoma HepG2 cell line (83). More-
over, Febriansah et al. (78) detected apoptosis in MCF-7 
cells by acridine orange/ethidium bromide double stain-
ing after treatment with 3.5 µM of HES, which is a con-
centration far below the doses we used. Our results are 
in agreement with these reports and confirm that HES 
induces apoptosis in breast cancer cells. Our results are 
also in line with Li et al. (84); the authors who also used 
NAR, to induce apoptosis in MDA-MB-231 cells. Af-
ter QUE treatment, Choi et al. (85) detected apoptosis 
in MDA-MB-453 cells, another TNBC line, similar to 
research by Rivera et al. (86) and in line with our own 
results on different breast cancer cells.
In agreement with our results, a time- and dose-de-
pendent end cell cycle arrest of MDA-MB-231 cells at 
G2/M phase after API treatment was reported by Tseng 
et al. (87), though they used lower concentrations of the 
flavonoid. Similarly, Lin et al. (88) demonstrated that 
API induced arrest at the G2/M phase and G0/G1 phase 
in MDA-MB-231 and MCF-7 cells, respectively. Tsub-
oy et al. (81) showed that 10 and 25 μM of GEN arrested 
MCF-7 cells at the G0/G1 phase, as we also observed, 
however with higher concentrations. Interestingly, GEN 
enhanced the radiosensitivity of both MCF-7 and MDA-
MB-231 cells via G2/M cell cycle arrest (85). Dourado 
et al. (89) didn’t observed any significant change in cell 
cycle progression on leukemia cells treated with HES. A 
dose-dependent cell cycle arrest in the G0/G1 phase was 
induced by NAR in urinary bladder cancer cells (90), 
and similarly, a cell cycle arrest in G0/G1 phase was 
induced by QUE in HT-29 colon cancer cells (91).
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In the review by Nabavi et al. (92), API suppressed 
MAPK (mitogen-activated protein kinases) in breast 
cancer, while NF-κβ and VEGF (vascular endothelial 
growth factor) as well as PI3K/AKT (phosphatidylino-
sitol-4,5-bisphosphate 3-kinase / Protein kinase B) and 
ErbB2 expression were all down-regulated. Long et al. 
(93) showed that API (> 10μM) downregulated ERα 
and AIB1 expression levels, and also inhibited multiple 
protein kinases, including p38, PKA, MAPK and AKT, 
in MCF-7 cells. The antiproliferative proapoptotic ef-
fect of API was mediated by ERβ, in MDA-MB-231 
cells (Mak et al.) (94). 
Fang et al. (95) suggested that GEN induced activa-
tion of ATR signaling in MDA-MB-231 cells. Interest-
ingly, GEN activated the BRCA1-A and -B complexes 
via the ATR signaling pathway. GEN induced changes 
of 23 signaling molecules, in ATM/ATR-mediated DNA 
damage response. Zhang et al (96) indicated that high 
levels of GEN promoted changes in DEG (degenerin) 
expression. Forty-seven DEGs are involved the cell 
cycle, including CDC20, BUB1, MCM2 and cyclin B1, 
thus indicating as the cell cycle pathway represents a 
relevant target in breast cancer treatment. 
Febriansah et al. (78), showed that HES exhibited 
a synergism in Pgp-expression through inhibition of 
MCF-7/Dox cells (doxorubicin-resistant), as well as in-
creased sensitivity of these cells to doxorubicin, a wide-
ly used chemotherapeutic agent.
Kaur et al. (97) recognized QUE and NAR, as in-
ducers of BCRP, the breast cancer resistance protein. 
Schindler et al. (98) showed that NAR inhibited the re-
lease of VEGF from breast cancer cells. Ranganathan 
et al. (79) reported that, in the MCF-7 cells, NAR sup-
pressed Twist, p16 and p21 via the p38MAPK path-
way. QUE also increased FasL mRNA expression and 
p51, p21 and GADD45 signaling activities, as well 
as Foxo3a protein levels and nuclear translocation in 
MDA-MB-231 cells (99). Generally, we observed, that 
MCF-7 cells were more sensitive on flavonoids treat-
ment, it is probably due the estrogen receptor. Further 
research in hormone dependent therapy should be con-
ducted. 
In conclusion, a diet rich in flavonoids from natural 
sources (plant foods and bee products) may represent a 
protective lifestyle in (breast) cancer chemoprevention 
as well as promising anticancer phytotherapeutics might 
be developed from food flavonoids.
This comparative in vitro study assessed the effects 
of selected flavonoids found in propolis on MDA-
MB-231 and MCF-7 breast cancer cells. In particular, 
a correlation was demonstrated between flavonoids and 
their anticancer properties. Indeed, flavonoids induced 
a dose-dependent cytotoxicity as well as apoptosis and 
cell cycle arrest in cancer cells. However, as previously 
mentioned, the composition of propolis varies, depend-
ing on the geographic origin and other environmental 
factors, and, therefore, the actual content of these bioac-
tive components is variable. In the future, nano-formu-
lation of flavonoids will certainly improve their delivery 
and targeting, while further studies are needed to fully 
ascertain their in human bioavailability, efficacy and 
safety.
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